- Home
- ASG vs FHTX Comparison
ASG vs FHTX Comparison
Compare ASG & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- FHTX
- Stock Information
- Founded
- ASG 1986
- FHTX 2015
- Country
- ASG United States
- FHTX United States
- Employees
- ASG N/A
- FHTX N/A
- Industry
- ASG Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- ASG Finance
- FHTX Health Care
- Exchange
- ASG Nasdaq
- FHTX Nasdaq
- Market Cap
- ASG 327.2M
- FHTX 517.9M
- IPO Year
- ASG N/A
- FHTX 2020
- Fundamental
- Price
- ASG $5.72
- FHTX $7.23
- Analyst Decision
- ASG
- FHTX Strong Buy
- Analyst Count
- ASG 0
- FHTX 5
- Target Price
- ASG N/A
- FHTX $16.00
- AVG Volume (30 Days)
- ASG 324.3K
- FHTX 133.0K
- Earning Date
- ASG 01-01-0001
- FHTX 10-31-2024
- Dividend Yield
- ASG 8.09%
- FHTX N/A
- EPS Growth
- ASG N/A
- FHTX N/A
- EPS
- ASG N/A
- FHTX N/A
- Revenue
- ASG N/A
- FHTX $35,185,000.00
- Revenue This Year
- ASG N/A
- FHTX N/A
- Revenue Next Year
- ASG N/A
- FHTX $15.40
- P/E Ratio
- ASG N/A
- FHTX N/A
- Revenue Growth
- ASG N/A
- FHTX 61.95
- 52 Week Low
- ASG $4.47
- FHTX $2.70
- 52 Week High
- ASG $5.71
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- ASG 64.98
- FHTX 41.45
- Support Level
- ASG $5.66
- FHTX $7.24
- Resistance Level
- ASG $5.65
- FHTX $8.35
- Average True Range (ATR)
- ASG 0.05
- FHTX 0.57
- MACD
- ASG 0.00
- FHTX -0.08
- Stochastic Oscillator
- ASG 85.71
- FHTX 16.02
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.